Skip to main
EVAX

EVAX Stock Forecast & Price Target

EVAX Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Evaxion AS has demonstrated a strong position in the neoantigen cancer vaccine space, with the PIONEER AI model achieving an improved prediction accuracy of 81% for identifying immunogenic neoantigens, reinforcing its competitive edge. The clinical outcomes of patients treated with the EVX-01 vaccine in combination with pembrolizumab reflect a promising overall response rate (ORR) of 75%, which exceeds previous data, thus indicating the potential for effective treatment options in oncology. Furthermore, the sustained patient responses and favorable safety profile contribute to a heightened optimism regarding Evaxion's innovative approach to immunotherapy and its ongoing commitment to address significant unmet medical needs in cancer treatment.

Bears say

Evaxion AS's stock has experienced a negative reaction despite the positive data update for its EVX-01 program, primarily due to investor disappointment regarding the lack of a clear signal on the program's potential contribution to the company's financial outlook. This may indicate a gap between market expectations and the company's current capabilities or communication regarding its product pipeline. Additionally, the overall sentiment reflects concerns about the sustainability of the company’s innovative approaches in a competitive biotech landscape, which could hinder investor confidence and impact future funding opportunities.

EVAX has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Evaxion Biotech A/S and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Evaxion Biotech A/S (EVAX) Forecast

Analysts have given EVAX a Strong Buy based on their latest research and market trends.

According to 3 analysts, EVAX has a Strong Buy consensus rating as of Dec 24, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Evaxion Biotech A/S (EVAX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.